Prof Grob speaks with ecancer at EADO 2017 about successes with combined immunotherapy and radiotherapy to treat metastatic melanoma.

By treating brain metastases with upfront Gammaknife radiosurgery followed by systemic therapy, he reports disease control beyond that achieved with targeted therapy along.

While there is no long-term survival or toxicity data matured so far, Prof Grob notes that the gains in overall survival are still significant and offer patients improved short-term survival.

Brain metastases were also discussed by Dr Peter Mohr, here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.